Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: Focus on romiplostim and eltrombopag

Jyoti D. Chouhan, Jon D. Herrington

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Idiopathic thrombocytopenic purpura (ITP) is a platelet disorder that affects approximately 1 in 10,000 people. In adults, the rate of spontaneous remission is only 5%, and generally, it is a chronic disease persisting for more than 6 months. Chronic refractory ITP may be defined as the failure of any modality to keep the platelet count above 20 x 103/mm3 for an appreciable time without unacceptable toxicity. Many pharmacologic treatments have been used to manage chronic refractory ITP by attempting to increase platelet counts by decreasing the rate of destruction of these cells. They include, but are not limited to, azathioprine, danazol, dapsone, combination chemotherapy, cyclosporine, and rituximab. However, these therapies offer modest response rates and can cause adverse events that necessitate drug discontinuation. The recent United States Food and Drug Administration approval of the thrombopoietin mimetics, romiplostim and eltrombopag, has provided clinicians with a novel approach for treating chronic refractory ITP. By stimulating platelet production, these drugs offer patients with this disease an alternative to the other agents. The preapproval phase III study with subcutaneous romiplostim showed significantly higher overall response rates versus placebo in both splenectomized and nonsplenectomized patients (83% for romiplostim vs 7% for placebo, p<0.0001). Twenty-five percent of patients receiving romiplostim achieved a platelet count greater than 50 x 10 3/mm3 after 1 week, and 50% achieved this platelet count within 2-3 weeks. The preapproval phase III study with oral eltrombopag demonstrated that 70% of patients receiving 50 mg/day and 81% of patients receiving 75 mg/day achieved a platelet count of at least 50 x 10 3/mm3 by day 43 (p<0.001 vs placebo for both 50 and 75 mg). Forty-four percent and 62% of patients achieved a platelet count of at least 50 x 103/mm3 by day 8 with eltrombopag 50 and 75 mg/day, respectively. When deciding which of these agents to prescribe, considerations include oral versus injectable dosage form, adverse-event profiles, and patient adherence with both taking the drug and keeping clinic appointments for monitoring of platelet counts. Several studies are under way to evaluate these drugs in chronic refractory ITP as well as other disease states. Long-term data will also be needed to assess the safety and efficacy of these agents.

Original languageEnglish (US)
Pages (from-to)666-683
Number of pages18
Issue number7
StatePublished - Jul 2010
Externally publishedYes


  • AMG 531
  • Eltrombopag
  • ITP
  • Idiopathic thrombocytopenic purpura
  • Romiplostim
  • SB497115
  • TPO
  • Thrombopoietin

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: Focus on romiplostim and eltrombopag'. Together they form a unique fingerprint.

Cite this